Alvotech
ALVOW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 7 institutions reported holding it in 13F filings for Q2 2026, worth $1.16M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVO
13F holders, Q3 2025
Institutional positions in Alvotech as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- 0 vs. Q2 2025
- Shares held
- 5.10M
- −53.9K (−1.0%) vs. Q2 2025
- Total value
- $7.74M
- −$1.34M (−14.8%) vs. Q2 2025
- New holders
- 2
- 1 more added
- Sold out
- 2
- 3 more reduced
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALVOW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 7 | $1.16M |
| Q1 2026 | 6 | $1.29M |
| Q4 2025 | 8 | $3.30M |
| Q3 2025 | 10 | $7.74M |
| Q2 2025 | 11 | $9.09M |
| Q1 2025 | 11 | $7.80M |
| Q4 2024 | 10 | $16.3M |
| Q3 2024 | 10 | $15.7M |
| Q2 2024 | 12 | $15.8M |
| Q1 2024 | 12 | $22.4M |
| Q4 2023 | 12 | $14.4M |
| Q3 2023 | 13 | $9.88M |
| Q2 2023 | 14 | $7.22M |
| Q1 2023 | 15 | $13.3M |
| Q4 2022 | 23 | $5.39M |
| Q3 2022 | 26 | $4.54M |
| Q2 2022 | 29 | $5.40M |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Alvotech; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Oaktree Capital Management LPSuperinvestorOaktree Capital | 4,666,667 | $7.09M | 0.12% | 00.0% | Unchanged |
| Linden Advisors LP | 252,884 | $370.5K | 0.00% | 00.0% | Unchanged |
| Arena Capital Advisors, LLC- CA | 60,714 | $92.2K | 0.04% | 00.0% | Unchanged |
| Jane Street Group, LLC | 56,256 | $85.4K | 0.00% | −40.0% | Reduced |
| Moore Capital Management, LP | 50,000 | $75.9K | 0.00% | 00.0% | Unchanged |
| Sculptor Capital LP | 6,543 | $9.55K | 0.00% | −43,196−86.8% | Reduced |
| Highbridge Capital Management LLC | – | $8.88K | 0.00% | – | New |
| Clear Street Group Inc. | 5,828 | $8.85K | 0.00% | +5,828 | New |
| Bank of America Corp | 298 | $452 | 0.00% | +99+49.7% | Added |
| UBS Group AG | 26 | $39 | 0.00% | −2,647−99.0% | Reduced |
| Bluefin Capital Management, LLC | 0 | $0 | 0.00% | −12,608−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −1,397−100.0% | Sold out |
| Clear Street LLC | – | – | – | – | Not filed |